Neurodegenerative disease management最新文献

Does menopause affect MS progression? Evidence and ongoing debates.

IF 2.3

Neurodegenerative disease management Pub Date : 2025-04-07 DOI: 10.1080/17582024.2025.2489878

L Lorefice, E Ferraro

引用次数: 0

Real-world evidence of riluzole on survival and ALSFRS change in a Chinese ALS cohort.

IF 2.3

Neurodegenerative disease management Pub Date : 2025-04-04 DOI: 10.1080/17582024.2025.2488235

JingSi Jiang, XiaoGang Li, YuXin Mi, YiYing Wang, YanXi Heng, ZhiWen Li, Min Deng

{"title":"Real-world evidence of riluzole on survival and ALSFRS change in a Chinese ALS cohort.","authors":"JingSi Jiang, XiaoGang Li, YuXin Mi, YiYing Wang, YanXi Heng, ZhiWen Li, Min Deng","doi":"10.1080/17582024.2025.2488235","DOIUrl":"https://doi.org/10.1080/17582024.2025.2488235","url":null,"abstract":"Aims: This study aimed to evaluate the effects of riluzole on survival and changes in ALS Functional Rating Scale (ALSFRS) among Chinese patients with Amyotrophic Lateral Sclerosis (ALS).Patients & methods: Propensity score matching was used to balance baseline variables between the riluzole group (n = 238) and control group (n = 454). Survival was analyzed using Kaplan - Meier curves and Cox regression, while multivariable linear regression assessed ALSFRS changes at 6 and 12 months. Subgroup analyses were conducted to identify potential responders.Results: Riluzole did not significantly improve survival (p = 0.478) or ALSFRS changes at 6 months (p = 0.380) or 12 months (p = 0.175). Subgroup analyses revealed no survival benefit in any subgroup, and further stratification showed inconsistent adverse effects on ALSFRS scores.Conclusions: Riluzole neither prolonged survival nor slowed functional decline in Chinese ALS patients, with no subgroup demonstrating a better response.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-11"},"PeriodicalIF":2.3,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143780633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The calmodulin hypothesis of neurodegenerative diseases: searching for a common cure.

IF 2.3

Neurodegenerative disease management Pub Date : 2025-04-02 DOI: 10.1080/17582024.2025.2488230

Danton H O'Day

引用次数: 0

Investigation of the significance of quantitative MRI parameters in differentiating PSP from MSA patients.

IF 2.3

Neurodegenerative disease management Pub Date : 2025-03-27 DOI: 10.1080/17582024.2025.2481817

Halil Onder, Aynur Turan, Fatmanur Ugur, Selcuk Comoglu

{"title":"Investigation of the significance of quantitative MRI parameters in differentiating PSP from MSA patients.","authors":"Halil Onder, Aynur Turan, Fatmanur Ugur, Selcuk Comoglu","doi":"10.1080/17582024.2025.2481817","DOIUrl":"https://doi.org/10.1080/17582024.2025.2481817","url":null,"abstract":"Objective: To investigate the utility of quantitative MRI parkinsonism indices in discriminating between progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) patients.Methods: In our study including PSP and MSA patients, we calculated the radiological measures including superior cerebellar peduncle width, middle cerebellar peduncle width, third ventricle width, 3rdV/bifrontal width, pons/mesencephalon (P/M) ratio, P/M ratio 2.0, magnetic resonance parkinsonism index (MRPI), and MRPI 2.0 values. We also constituted a PMS scale to increase the discrimination power.Results: Comparisons between PSP and MSA patients revealed significant differences in the mesencephalon area, third ventricle width, 3rdV/bifrontal width, P/M ratio, P/M ratio 2.0, MRPI, and MRPI 2.0 values (p < 0.01 for all). The AUC values were acceptable for the third ventricle width, the 3rdV/bifrontal width ratio, the P/M ratio, the P/M 2 ratio, the MRPI and the MRPI-2. In distinguishing PSP, 0 points on the PMS scale had a negative predictive value (NPV) of 91%, whereas 3 points had a positive predictive value (PPV) of 85.7%.Conclusion: None of the MRI parameters reached a good diagnostic AUC in distinguishing PSP from MSA. However, the PMS scale we propose in this study may provide high PPVs and NPVs for differential diagnosis during desk-based evaluation.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-8"},"PeriodicalIF":2.3,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143720776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advanced Parkinson's disease and eligibility for device-aided therapies in Morocco: a multicenter cross-sectional study.

IF 2.3

Neurodegenerative disease management Pub Date : 2025-03-24 DOI: 10.1080/17582024.2025.2481818

Mohamed Daghi, Zineb Serhier, Abdelhakim Lakhdar, Hicham El Otmani

{"title":"Advanced Parkinson's disease and eligibility for device-aided therapies in Morocco: a multicenter cross-sectional study.","authors":"Mohamed Daghi, Zineb Serhier, Abdelhakim Lakhdar, Hicham El Otmani","doi":"10.1080/17582024.2025.2481818","DOIUrl":"10.1080/17582024.2025.2481818","url":null,"abstract":"Aim: This study investigates the prevalence and clinical features of advanced Parkinson's disease (APD) in Moroccan patients and evaluates their eligibility for Device-Aided Therapies (DATs), including Deep Brain Stimulation (DBS), Continuous Subcutaneous Apomorphine Infusion (CSAI), and Levodopa-Carbidopa Intestinal Gel infusion (LCIG).Methods: We conducted a cross-sectional study across 15 facilities in five cities within the Casablanca-Settat region, Morocco. We collected demographics, clinical, and health-related quality of life data. Logistic regression identified factors predicting disease progression and DATs eligibility.Results: This study included 370 patients with Parkinson's disease, of whom 44.6% (95%CI: 39.5%-49.8%) had APD. Each additional year of disease duration increased APD odds by 8% (ORa = 1.08, p = 0.047). Overall, 38.9% of patients qualified for at least one DAT, including 18.9% for DBS, 35.4% for CSAI, and 13.8% for LCIG; however, only one patient received DBS. Younger age at onset was associated with greater DATs eligibility, with each additional year reducing eligibility by 7% (ORa = 0.93, p < 0.001). Additionally, premotor REM sleep behavior disorder increased the odds of LCIG eligibility (ORa = 2.38, p = 0.009), while prior sports engagement nearly tripled the odds for CSAI (ORa = 2.87, p = 0.038).Conclusion: Although many Moroccan patients qualify for DATs, their use is minimal. Addressing access barriers is crucial to improve outcomes.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-12"},"PeriodicalIF":2.3,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143692736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real world effectiveness, persistence, tolerability, and safety of ofatumumab in clinical practice. ofatumumab在临床实践中的有效性、持久性、耐受性和安全性。

IF 2.3

Neurodegenerative disease management Pub Date : 2025-02-01 Epub Date: 2025-01-21 DOI: 10.1080/17582024.2025.2452150

Moein Amin, Tucker Harvey, Dan Michael Pineda, Ming-Hui Tai, Qiujun Shao, Brandon Brown, Abhijit Gadkari, Brandon Moss, Devon S Conway, Carrie M Hersh

{"title":"Real world effectiveness, persistence, tolerability, and safety of ofatumumab in clinical practice.","authors":"Moein Amin, Tucker Harvey, Dan Michael Pineda, Ming-Hui Tai, Qiujun Shao, Brandon Brown, Abhijit Gadkari, Brandon Moss, Devon S Conway, Carrie M Hersh","doi":"10.1080/17582024.2025.2452150","DOIUrl":"10.1080/17582024.2025.2452150","url":null,"abstract":"Aims: To describe the 12-month effectiveness, persistence, tolerability, and safety of ofatumumab (OMB), a highly effective disease-modifying therapy (DMT) for relapsing multiple sclerosis (MS), in a real-world MS population.Patients & methods: Electronic medical records of patients starting OMB from October 2020 to August 2022 at two comprehensive MS centers were reviewed. Demographics and disease characteristics and 6- and 12-month clinical, patient-reported, and radiologic outcome measures were analyzed.Results: A total of 175 patients started OMB with mean age 44.9 (SD 10.4) and disease duration 13.6 (SD 9.6) years. The cohort was 74% female, included 81% White and 13% Black American patients, and consisted of 80% relapsing-remitting MS or clinically isolated syndrome. Most (87%) had prior DMT exposure with 38% switching from high efficacy DMT. Over 12 months, 9.7% discontinued OMB (mean 117 days, SD 99.2), with tolerability issues being the most common reason. Thirty-nine (22%) had relapses in the year before starting OMB. By 12 months, only 1 relapse had occurred after approximately 4 months post-treatment initiation.Discussion: This real-world study demonstrated that OMB is highly effective with robust persistence and good safety and tolerability by 12-month follow-up. Further analyses are planned to examine longer-term outcomes.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"27-36"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11938955/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143009072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in the management of Alzheimer's disease.

IF 2.3

Neurodegenerative disease management Pub Date : 2025-02-01 Epub Date: 2025-02-06 DOI: 10.1080/17582024.2025.2463313

Maheen Nawaz, Ahmed Ali Khan, Muhammad Shaheer Bin Faheem

引用次数: 0

Friedreich ataxia: what can we learn from non-GAA repeat mutations? 弗里德里希共济失调：我们能从非GAA重复突变中学到什么？

IF 2.3

Neurodegenerative disease management Pub Date : 2025-02-01 Epub Date: 2025-01-15 DOI: 10.1080/17582024.2025.2452147

David R Lynch, M Shen, Robert B Wilson

引用次数: 0

Economic evaluation of mHealth solutions in PD: where do we stand?

IF 2.3

Neurodegenerative disease management Pub Date : 2025-02-01 Epub Date: 2025-02-18 DOI: 10.1080/17582024.2025.2467020

Foivos S Kanellos, Ermioni Petkou, Spyridon Konitsiotis, Yannis V Simos, Lampros Lakkas, Dimitrios Peschos, Konstantinos I Tsamis

引用次数: 0

Investigation of nonmotor symptoms and their clinical correlates in patients with Parkinson's disease.

IF 2.3

Neurodegenerative disease management Pub Date : 2025-02-01 Epub Date: 2025-03-17 DOI: 10.1080/17582024.2025.2468145

H Onder, S Comoglu

{"title":"Investigation of nonmotor symptoms and their clinical correlates in patients with Parkinson's disease.","authors":"H Onder, S Comoglu","doi":"10.1080/17582024.2025.2468145","DOIUrl":"10.1080/17582024.2025.2468145","url":null,"abstract":"Background: In this study, we aimed to investigate the clinical features of a large group of patients with Parkinson's disease (PD), paying particular attention to the nonmotor symptom (NMS) load. Secondly, we aimed to investigate the clinical correlates of NMSs using the results of various clinical assessments.Methods: Data from all PD patients who visited our movement disorders clinic between January 2023 and March 2024 were retrospectively reviewed. We included the data of all patients whose information regarding clinical features and extensive scale results were available.Results: Overall, we included data from 285 PD patients with a mean age of 64.5 ± 10.0 years (F/M = 119/166). The median scores of the MDS-UPDRS subparts were 9 for MDS-UPDRS-1 and 30 for MDS-UPDRS-3 (off). The median NMSS score was 38 (range: 229), and 46% of the patients had severe to very severe disease in terms of NMS burden. The regression analyses revealed the MDS-UPDRS 3 score, FES-I score, and RBD (0.9772 + 0.453*MDS-UPDRS 3 + 0.724 * FES-I + 15.192*RBD) as predictors of the NMS scale.Conclusions: We found a very high NMS burden in our PD cohort. Remarkably, RBD, motor stage, and concern about falling were found to correlate with NMS load.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"47-55"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11938959/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143648187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0